India issues urgent public health notice for all GLP-1 drugs including semaglutide
The IPC has called for close monitoring of adverse reactions to semaglutide and other GLP-1 medications amid rising usage. Authorities emphasize post-marketing surveillance to identify side-effects and ensure safety for patients using these popular diabetes and weight-loss therapies.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
